Jupiter - RD006296 version 6

• Research type

  Research Study

• Full title

  Jupiter – Measuring Elecsys β-Amyloid (1-42) II, Phospho-Tau (181P), Total-Tau, and Possibly β-Amyloid (1-40) in CSF Samples supporting Phase 3b/4 Clinical Trial of 221AD305 (BIIB037)

• IRAS ID

  324608

• Contact name

  Craig Ritchie

• Contact email

  craig.ritchie@ed.ac.uk

• Sponsor organisation

  Roche Diagnostics International Ltd.

• Duration of Study in the UK

  0 years, 11 months, 30 days

• Research summary

  The primary objective of the study is to analyze the CSF measurements of β-Amyloid (1-42) (Aβ 42) and Phospho-Tau (181P) (pTau) using Elecsys β-Amyloid (1-42) CSF II and Elecsys Phospho-Tau (181P) CSF in the screening samples of the phase 3b/4 clinical trial of 221AD305 (BIIB037) to enroll patients based on the pTau/Aβ 42 ratio as evidence of amyloid pathology.

• REC name

  Yorkshire & The Humber - Leeds West Research Ethics Committee

• REC reference

  23/YH/0177

• Date of REC Opinion

  20 Oct 2023

• REC opinion

  Further Information Unfavourable Opinion